| OpenWorm: an open-science approach to modeling Caenorhabditis elegans B Szigeti, P Gleeson, M Vella, S Khayrulin, A Palyanov, J Hokanson, ... Frontiers in computational neuroscience 8, 137, 2014 | 186 | 2014 |
| Self-blinding citizen science to explore psychedelic microdosing B Szigeti, L Kartner, A Blemings, F Rosas, A Feilding, DJ Nutt, ... elife 10, e62878, 2021 | 172 | 2021 |
| A blueprint for human whole-cell modeling B Szigeti, YD Roth, JAP Sekar, AP Goldberg, SC Pochiraju, JR Karr Current opinion in systems biology 7, 8-15, 2018 | 81 | 2018 |
| Emerging whole-cell modeling principles and methods AP Goldberg, B Szigeti, YH Chew, JAP Sekar, YD Roth, JR Karr Current opinion in biotechnology 51, 97-102, 2018 | 80 | 2018 |
| Searching for motifs in the behaviour of larval Drosophila melanogaster and Caenorhabditis elegans reveals continuity between behavioural states B Szigeti, A Deogade, B Webb Journal of The Royal Society Interface 12 (113), 20150899, 2015 | 54 | 2015 |
| Are ecstasy induced serotonergic alterations overestimated for the majority of users? B Szigeti, AR Winstock, D Erritzoe, LJ Maier Journal of Psychopharmacology 32 (7), 741-748, 2018 | 28 | 2018 |
| Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression B Szigeti, B Weiss, FE Rosas, D Erritzoe, D Nutt, R Carhart-Harris Psychological medicine, 1-8, 2024 | 24 | 2024 |
| The difference between ‘placebo group’and ‘placebo control’: A case study in psychedelic microdosing B Szigeti, D Nutt, R Carhart-Harris, D Erritzoe Scientific Reports 13 (1), 12107, 2023 | 24* | 2023 |
| Expectancy effects in psychedelic trials B Szigeti, B Heifets Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2024 | 19 | 2024 |
| Inconsistencies in C. elegans behavioural annotation B Szigeti, T Stone, B Webb BioRxiv, 066787, 2016 | 7 | 2016 |
| The OpenWorm Project: currently available resources and future plans P Gleeson, M Cantarelli, M Currie, J Hokanson, G Idili, S Khayrulin, ... BMC neuroscience 16 (Suppl 1), P141, 2015 | 7 | 2015 |
| Bayesian analysis of real-world data as evidence for drug approval: remembering Sir Michael Rawlins B Szigeti, LD Phillips, D Nutt British Journal of Clinical Pharmacology 89 (9), 2646-2648, 2023 | 6 | 2023 |
| Guess of Treatment questionnaire B Szigeti, D Nutt, R Carhart-Harris, D Erritzoe OSF, 2024 | | 2024 |
| Self-blinding, citizen science microdosing study: an insight into the study design of an innovative approach to investigating psychedelic effects A Wingert, B Szigeti, B Weiss, K Godfrey, O Mallon, D Nutt, D Erritzoe Neuroscience Applied 3, 104974, 2024 | | 2024 |
| Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial S Baumann, R Carhart-Harris, D Nutt, D Erritzoe, B Szigeti PsyArXiv, 2022 | | 2022 |
| Behavioural motifs of larval Drosophila melanogaster and Caenorhabditis elegans B Szigeti The University of Edinburgh, 2017 | | 2017 |
| The OpenWorm project and the behavioural Turing test B Szigeti Frontiers of Natural Computing 2012, 2012 | | 2012 |
| Unmasking bias and MDMA-assisted therapy B Szigeti, E Bradley, J Woolley Center for Open Science, 0 | | |
| Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: An Open-Label Pilot Trial ER Bradley, K Sakai, G Fernandes-Osterhold, B Szigeti, C Ludwig, ... | | |